Current strategies for immunosuppression following organ transplantation focus on the prevention of acute rejection. As new generations of immunosuppressants have been developed, acute rejection rates have diminished markedly. The new challenge, then, is to prevent the devastating complications of chronic rejection, which have remained largely unchanged over the decades. The process of chronic ...

Immunosuppressive and anti-inflammatory agents are able to generate tolerogenic DCs, leading, in some cases, to induction or enhancement of regulatory T cells with suppressive activity. This novel mechanism of action, shared by several immunosuppressive and anti-inflammatory agents, is becoming firmly established and contributes to explain their functional properties. The possibility to manipul...

Anaemia commonly occurs following renal transplantation related to surgical blood loss, myelosuppression from immunosuppressive agents, antimicrobial prophylaxis and persisting renal impairment. A rare cause of anaemia after solid organ transplantation is alloimmune haemolysis due to antibodies from donor-derived lymphocytes accompanying the donor organ. We report the case of a 27-year-old pati...

Although surgical techniques, post-transplant care medicine, and immunosuppressants have been greatly improved, permanent acceptance of renal allograft remains a clinical challenge owing to the appearance of various influencing factors. To predict graft dysfunction, development of noninvasive biomarkers is becoming a highlighted research topic in the field of renal transplantation, which provid...

The immunosuppressant FK506 binds Plasmodium falciparum FK-506 binding protein 35 (PfFKBP35) and shows anti-malarial activity. To understand molecular mechanism of the drug on the parasite, we have done NMR studies. Here, we report the assignment of FK506-binding domain of PfFKBP35.

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn’s Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Peter N. Le, MD,* Julia B. Greer, MD, MPH, Ioannis Oikonomou, MD, Wolfgang H. Schraut, MD, Corey A. Siegel, MD,jj Raymond K. Cross, MD, MS, Stefan D. Holubar, MD, MS,** Andrew Tinsley, MD, Walter A. Koltun, MD, David G. Binion, MD, and Migu...

A component in extracts of Group A streptococci suppresses antibody formation in mice against heterologous erythrocyte and protein antigens. Large doses are not toxic and repeated injection does not change its effectiveness. It is most effective when injected 1 or 2 days before antigen and it is not suppressive when given after antigen. The active factor occurs as a large polydisperse complex a...

The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that has been brought forward from other transplant indications. Widely employed on the basis of few small randomized studies, and mostly single-center experience or empirical expert knowledge, anti-rejection therapeutic strategies in pulmonary transplantation have hardly been rigorously evaluated in ...